|
Multiple Myeloma
|
|
Smoldering
|
Ithaca (SMM)
Phase 3 randomized, open label, multicenter study of Isatuximab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma
|
Plan to open 30Jun2020
|
|
Newly Diagnosed
|
GSK2857916 DREAMM 9 (ND MM)
A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation
|
Open to recruitment
|
|
IRiL (ND MM)
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma
|
Open to recruitment
|
|
MM21 (ND MM)
A multicentre, single arm, study of Daratumumab-Lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail Bortezomib-based induction therapy.
|
Open to recruitment
|
|
Relapsed Refractory
|
AbbVie M15-654 (R/R MM)
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
|
Open to recruitment
|
|
Genentech GO41582 (R/R MM)
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics of Escalating Doses of RO7297089 In Patients With Relapsed or Refractory Multiple Myeloma
|
Plan to open 30Jun2020
|
|
GSK2857916 DREAMM 3 (R/R MM)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK2857916 DREAMM 5 (R/R MM)
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma
|
Open to recruitment
|
|
GSK207497 DREAMM 6 (R/R MM)
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma
|
Open to recruitment
|
|
TCD15484 Sub-Cut Isatuximab (R/R MM)
A multi-center, open-label, Phase 1b study to assess the pharmacokinetics, safety, and efficacy of subcutaneous and intravenous Isatuximab (SAR650984) in combination with Pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma
|
Open to recruitment
|
|
Chronic Lymphocytic Leukaemia & Lymphomas
|
|
Treatment Naïve
|
ALLG HD10 (TN HL)
Treatment optimization trial in the first-line treatment of advanced stage Hodgkin Lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
|
Open to Recruitment
|
|
BGB3111_304 (TN CLL)
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
|
Open to recruitment
|
|
BGB-3111-306 Mangrove (TN MCL)
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
|
Open to recruitment
|
|
PCYC1143 (TN MCL)
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
|
Open to recruitment
|
|
Treatment Naïve &
Relapsed Refractory
|
Assure (TN CLL, RR CLL)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic leukaemia
|
Open to Recruitment
|
|
TG-1701-110 (R/R CLL, WM, NHL, TN CLL, WM, MCL)
A Phase 1 Pharmacokinetic and Pharmacodynamics Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies
|
Open to recruitment
|
|
Relapsed Refractory
|
Amgen 20140286 - Subcut Blinatumomab (R/R NHL)
A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma
|
Open to recruitment
|
|
Ascentage APG-2575-001 (R/R CLL, WM, DLBCL, AML, NHL, MCL)
A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with hematologic malignancies
|
Open to recruitment
|
|
BGB-3111-305 Alpine (R/R CLL)
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic leukaemia or Small Lymphocytic Lymphoma
|
Open to recruitment
|
|
BGB-3111-LTE1 (R/R DLBCL, FL, CLL, SLL, MCL)
An Open-label, Multi-center, Long-term Extension
Study of Zanubrutinib (BGB-3111) in Patients with B Cell
Malignancies
|
Open to recruitment
|
|
BGB-A317-210 TIRHOL (R/R cHL)
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
|
Open to recruitment
|
|
Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic leukaemia
|
Open to recruitment
|
|
GENMAB GCT3013-01 (R/R DLBCL and FL)
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
|
Plan to open 30Jun2020
|
|
MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
|
Open to recruitment
|
|
Roche GO41943 (R/R DLBCL)
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of RO7082859 or Mosunetuzumab (RO7030816) in Combination with Gemcitabine plus Oxaliplatin in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
|
Open to recruitment
|
|
Acute Myeloid Leukaemia & Myelodysplastic Syndrome
|
|
Treatment Naïve
|
Culminate (TN AML)
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukaemia who are not Candidates for Intensive Chemotherapy
|
Open to Recruitment
|
|
Registries / Other
|
|
Myeloma 1000 Registry
The Myeloma 1000 Project
|
Open to recruitment
|
|
MRDR Registry
Myeloma & Related Diseases Registry
|
Open to recruitment
|
|
NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)
|
Open to recruitment
|
|
Carfilzomib Retrospective 20170766
Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific
|
Open to recruitment
|
|
Bleeding Disorders
|
|
TREATT
TREATT Trial to Evaluate Tranexamic acid therapy in Thrombocytopenia. A double blind randomized controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with hematological malignancies with severe thrombocytopenia.
|
|